- Home
- ALLO vs PFLT Comparison
ALLO vs PFLT Comparison
Compare ALLO & PFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALLO | PFLT |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.6M | 742.1M |
| IPO Year | 2018 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ALLO | PFLT |
|---|---|---|
| Price | $2.07 | $7.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 6 |
| Target Price | $8.35 | ★ $10.50 |
| AVG Volume (30 Days) | ★ 9.0M | 1.1M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 14.12% |
| EPS Growth | ★ 34.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.16 |
| Revenue Next Year | $142,416.42 | N/A |
| P/E Ratio | ★ N/A | $24.14 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.99 | $7.03 |
| 52 Week High | $4.46 | $10.88 |
Technical Indicators
Market Signals| Indicator | ALLO | PFLT |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 40.03 |
| Support Level | $1.85 | N/A |
| Resistance Level | $2.36 | $8.35 |
| Average True Range (ATR) | 0.13 | 0.22 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 60.00 | 42.27 |
Price Performance
Historical ComparisonAbout ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
About PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate both current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generates revenue in the form of interest income on the debt securities and dividends.